# A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

> **NCT04563026** · PHASE2 · COMPLETED · sponsor: **Durect** · enrollment: 307 (actual)

## Conditions studied

- Alcoholic Hepatitis

## Interventions

- **DRUG:** DUR-928 30 mg
- **DRUG:** DUR-928 90 mg
- **DRUG:** Placebo+ Standard of Care (SOC)

## Key facts

- **NCT ID:** NCT04563026
- **Lead sponsor:** Durect
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-22
- **Primary completion:** 2023-09-06
- **Final completion:** 2023-09-06
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2024-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04563026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04563026, "A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04563026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*